{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T03:15:16Z","timestamp":1776222916723,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003407","name":"MIUR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.esmoop.2021.100133","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T20:36:26Z","timestamp":1620678986000},"page":"100133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["High BRAF variant allele frequencies are associated with distinct pathological features and responsiveness to target therapy in melanoma patients"],"prefix":"10.1016","volume":"6","author":[{"given":"E.","family":"Berrino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Balsamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pisacane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Becco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Miglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Caravelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Poletto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Paruzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Debernardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Piccinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Zaccagna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Rescigno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Aglietta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Sapino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Carnevale-Schianca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Venesio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6892","key":"10.1016\/j.esmoop.2021.100133_bib2","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100133_bib3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40257-013-0025-9","article-title":"Optimal management of metastatic melanoma: current strategies and future directions","volume":"14","author":"Batus","year":"2013","journal-title":"Am J Clin Dermatol"},{"issue":"7","key":"10.1016\/j.esmoop.2021.100133_bib4","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","year":"2015","journal-title":"Cell"},{"issue":"17","key":"10.1016\/j.esmoop.2021.100133_bib5","first-page":"6483","article-title":"NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression","volume":"9","author":"Omholt","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"26","key":"10.1016\/j.esmoop.2021.100133_bib6","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100133_bib7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.esmoop.2021.100133_bib8","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100133_bib9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/modpathol.2017.104","article-title":"Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine","volume":"31","author":"Cheng","year":"2018","journal-title":"Mod Pathol"},{"issue":"7","key":"10.1016\/j.esmoop.2021.100133_bib10","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/bjc.2016.44","article-title":"BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival","volume":"114","author":"Hugdahl","year":"2016","journal-title":"Br J Cancer"},{"issue":"1-2","key":"10.1016\/j.esmoop.2021.100133_bib11","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000487440","article-title":"Heterogeneity in lung cancer","volume":"85","author":"de Sousa","year":"2018","journal-title":"Pathobiology"},{"issue":"12","key":"10.1016\/j.esmoop.2021.100133_bib12","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.3390\/ijms19123733","article-title":"Heterogeneity in colorectal cancer: a challenge for personalized medicine?","volume":"19","author":"Molinari","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.esmoop.2021.100133_bib13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3389\/fmed.2017.00227","article-title":"Tumor heterogeneity in breast cancer","volume":"4","author":"Turashvili","year":"2017","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100133_bib14","doi-asserted-by":"crossref","first-page":"e29336","DOI":"10.1371\/journal.pone.0029336","article-title":"Intra- and inter-tumor heterogeneity of BRAF(V600E) mutations in primary and metastatic melanoma","volume":"7","author":"Yancovitz","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100133_bib15","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/modpathol.2008.41","article-title":"In melanocytic lesions the fraction of BRAF V600E alleles is associated with sun exposure but unrelated to ERK phosphorylation","volume":"21","author":"Venesio","year":"2008","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100133_bib16","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/CMR.0000000000000088","article-title":"BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma","volume":"24","author":"Lebbe","year":"2014","journal-title":"Melanoma Res"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100133_bib17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/pcmr.12569","article-title":"Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma","volume":"30","author":"Mesbah Ardakani","year":"2017","journal-title":"Pigment Cell Melanoma Res"},{"issue":"35","key":"10.1016\/j.esmoop.2021.100133_bib18","doi-asserted-by":"crossref","first-page":"37895","DOI":"10.18632\/oncotarget.5634","article-title":"Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma","volume":"6","author":"Satzger","year":"2015","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100133_bib19","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1158\/1535-7163.MCT-17-1124","article-title":"BRAF gene copy number and mutant allele frequency correlate with time to progression in metastatic melanoma patients treated with MAPK inhibitors","volume":"17","author":"Stagni","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.esmoop.2021.100133_bib20","doi-asserted-by":"crossref","first-page":"D873","DOI":"10.1093\/nar\/gkt1198","article-title":"Locus Reference Genomic: reference sequences for the reporting of clinically relevant sequence variants","volume":"42","author":"MacArthur","year":"2014","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100133_bib21","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1755-148X.2011.00837.x","article-title":"BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site","volume":"24","author":"Bauer","year":"2011","journal-title":"Pigment Cell Melanoma Res"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100133_bib22","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1186\/s12885-017-3529-5","article-title":"Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care","volume":"17","author":"Heppt","year":"2017","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.esmoop.2021.100133_bib23","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1111\/jdv.12910","article-title":"Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma","volume":"29","author":"Pracht","year":"2015","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"11","key":"10.1016\/j.esmoop.2021.100133_bib24","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1038\/bjc.2013.622","article-title":"Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations","volume":"109","author":"Heinzerling","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2021.100133_bib25","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1186\/s12885-015-1515-3","article-title":"Variations of BRAF mutant allele percentage in melanomas","volume":"15","author":"Helias-Rodzewicz","year":"2015","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100133_bib26","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1158\/1055-9965.EPI-06-1038","article-title":"Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma","volume":"16","author":"Thomas","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100133_bib27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4161\/cbt.5.2.2429","article-title":"Detection of BRAF gene mutation in primary choroidal melanoma tissue","volume":"5","author":"Malaponte","year":"2006","journal-title":"Cancer Biol Ther"},{"issue":"15","key":"10.1016\/j.esmoop.2021.100133_bib28","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1158\/1078-0432.CCR-05-2447","article-title":"Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies","volume":"12","author":"Saldanha","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.esmoop.2021.100133_bib29","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1245\/s10434-014-3799-y","article-title":"Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site","volume":"21","author":"Gos","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2021.100133_bib30","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/bjc.2017.254","article-title":"Tumour mutation status and sites of metastasis in patients with cutaneous melanoma","volume":"117","author":"Adler","year":"2017","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100133_bib31","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1186\/s12885-019-5990-9","article-title":"Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma","volume":"19","author":"Doma","year":"2019","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100133_bib32","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/bjc.2017.220","article-title":"HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer","volume":"117","author":"Barnes","year":"2017","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100133_bib33","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/01.cmr.0000232300.22032.86","article-title":"NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing","volume":"16","author":"Edlundh-Rose","year":"2006","journal-title":"Melanoma Res"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100133_bib34","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/PAT.0000000000000314","article-title":"FOXP3+ T regulatory lymphocytes in primary melanoma are associated with BRAF mutation but not with response to BRAF inhibitor","volume":"47","author":"Leslie","year":"2015","journal-title":"Pathology"},{"issue":"13","key":"10.1016\/j.esmoop.2021.100133_bib35","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1158\/0008-5472.CAN-10-0118","article-title":"Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function","volume":"70","author":"Boni","year":"2010","journal-title":"Cancer Res"},{"issue":"10240","key":"10.1016\/j.esmoop.2021.100133_bib36","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100133_bib37","first-page":"24","article-title":"Impact of BRAF mutation status in the prognosis of cutaneous melanoma: an area of ongoing research","volume":"3","author":"Bhatia","year":"2015","journal-title":"Ann Transl Med"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100133_bib38","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jaad.2015.02.1113","article-title":"Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma","volume":"72","author":"Kim","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100133_bib39","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2133.2010.10185.x","article-title":"Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis","volume":"164","author":"Lee","year":"2011","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100133_bib40","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1186\/s12885-019-5864-1","article-title":"Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing","volume":"19","author":"Lokhandwala","year":"2019","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100133_bib41","doi-asserted-by":"crossref","first-page":"100002","DOI":"10.1016\/j.esmoop.2020.100002","article-title":"Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment","volume":"6","author":"Byeon","year":"2020","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100133_bib42","doi-asserted-by":"crossref","first-page":"17050","DOI":"10.1038\/s41598-019-53636-x","article-title":"A\u00a0comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of novel loss-of-function variants","volume":"9","author":"Ticha","year":"2019","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100133_bib43","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/bjc.2016.106","article-title":"A\u00a0UK feasibility and validation study of the VE1 monoclonal antibody immunohistochemistry stain for BRAF-V600E mutations in metastatic melanoma","volume":"115","author":"Lo","year":"2016","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100133_bib44","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/his.12992","article-title":"BRAF(V600E) and NRAS(Q61L\/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting","volume":"69","author":"Kakavand","year":"2016","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100133_bib45","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/09674845.2019.1592885","article-title":"Immunohistochemical detection of V600E BRAF mutation is a useful primary screening tool for malignant melanoma","volume":"76","author":"Orchard","year":"2019","journal-title":"Br J Biomed Sci"},{"issue":"8","key":"10.1016\/j.esmoop.2021.100133_bib46","doi-asserted-by":"crossref","first-page":"e0221123","DOI":"10.1371\/journal.pone.0221123","article-title":"Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay","volume":"14","author":"Vallee","year":"2019","journal-title":"PLoS One"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921000922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921000922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:25:49Z","timestamp":1761855949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702921000922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S2059702921000922"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100133","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High BRAF variant allele frequencies are associated with distinct pathological features and responsiveness to target therapy in melanoma patients","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100133","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100133"}}